A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

NCT04407234 · Completed

Last updated 2026-05-28

This study measures how quickly the stomach empties in adults who are overweight, with or without type 2 diabetes, after taking the medication tirzepatide.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 36 people

Who can join Ages 18–65 · all sexes

Timeline Started 2020-09 · est. completion 2021-01

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04407234 ↗

Description as written by the study sponsor.

The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes. The study will last about 13 weeks for each participant, including screening.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Tirzepatide administered SC.
Acetaminophen Drug

Acetaminophen administered orally.

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen
Sponsor	Eli Lilly and Company
Conditions studied	Overweight, Obesity, Diabetes Mellitus, Type 2
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04407234 ↗